Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy.

IF 2.4 3区医学 Q2 OPHTHALMOLOGY Graefe’s Archive for Clinical and Experimental Ophthalmology Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI:10.1007/s00417-024-06569-9

Ömer Özer, Levent Doğan, Zeki Baysal, Hakan Basir, Ali Türker Çıftçı, Pınar Eröz, Emin Serbülent Güçlü

{"title":"Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy.","authors":"Ömer Özer, Levent Doğan, Zeki Baysal, Hakan Basir, Ali Türker Çıftçı, Pınar Eröz, Emin Serbülent Güçlü","doi":"10.1007/s00417-024-06569-9","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to evaluate the clinical significance of blood-cell associated inflammation markers in patients with sickle cell disease (SCD) and sickle cell retinopathy (SCR).Methods: Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune inflammation index (SIII), systemic inflammation response index (SIRI), systemic inflammation modulation index (SIMI) and aggregate systemic inflammation index (AISI) were calculated. This study included 45 healthy controls (Group 1) and 100 SCD (Group 2). Patients in Group 2 were then divided into two groups: without SCR (Group 3) and with SCR (Group 4), and patients with SCR (Group 4) were further divided into two groups: non-proliferative sickle cell retinopathy (NPSCR) (Group 5) and proliferative sickle cell retinopathy (PSCR) (Group 6).Results: The mean values for NLR, PLR, SIII, SIRI, AISI, and SIMI were significantly higher in Group 2 compared to Group 1 (p = 0.011 for NLR, p = 0.004 for SIII, and p < 0.001 for others). Furthermore, AISI and SIMI parameters demonstrated statistically significant discriminatory power to distinguish Group 5 from Group 6 (p = 0.0016 and p = 0.0006, respectively).Conclusion: Given the critical role of inflammatory mechanisms in the pathogenesis of SCD and its related complications, the assessment of blood-cell-associated inflammatory markers may present a pragmatic and advantageous approach to the clinical oversight and therapeutic intervention of SCD.","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"3787-3796"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608169/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-024-06569-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to evaluate the clinical significance of blood-cell associated inflammation markers in patients with sickle cell disease (SCD) and sickle cell retinopathy (SCR).

Methods: Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune inflammation index (SIII), systemic inflammation response index (SIRI), systemic inflammation modulation index (SIMI) and aggregate systemic inflammation index (AISI) were calculated. This study included 45 healthy controls (Group 1) and 100 SCD (Group 2). Patients in Group 2 were then divided into two groups: without SCR (Group 3) and with SCR (Group 4), and patients with SCR (Group 4) were further divided into two groups: non-proliferative sickle cell retinopathy (NPSCR) (Group 5) and proliferative sickle cell retinopathy (PSCR) (Group 6).

Results: The mean values for NLR, PLR, SIII, SIRI, AISI, and SIMI were significantly higher in Group 2 compared to Group 1 (p = 0.011 for NLR, p = 0.004 for SIII, and p < 0.001 for others). Furthermore, AISI and SIMI parameters demonstrated statistically significant discriminatory power to distinguish Group 5 from Group 6 (p = 0.0016 and p = 0.0006, respectively).

Conclusion: Given the critical role of inflammatory mechanisms in the pathogenesis of SCD and its related complications, the assessment of blood-cell-associated inflammatory markers may present a pragmatic and advantageous approach to the clinical oversight and therapeutic intervention of SCD.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估伴有和不伴有视网膜病变的镰状细胞病的外周血炎症生物标志物。

背景：本研究旨在评估镰状细胞病（SCD）和镰状细胞视网膜病变（SCR）患者血液细胞相关炎症标记物的临床意义：本研究旨在评估镰状细胞病（SCD）和镰状细胞视网膜病变（SCR）患者血液细胞相关炎症指标的临床意义：方法：计算中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）、全身免疫炎症指数（SIII）、全身炎症反应指数（SIRI）、全身炎症调节指数（SIMI）和全身炎症总指数（AISI）。这项研究包括 45 名健康对照者（第 1 组）和 100 名 SCD 患者（第 2 组）。然后将第 2 组患者分为两组：无 SCR（第 3 组）和有 SCR（第 4 组）；将有 SCR（第 4 组）的患者进一步分为两组：非增殖性镰状细胞视网膜病变（NPSCR）（第 5 组）和增殖性镰状细胞视网膜病变（PSCR）（第 6 组）：结果：第 2 组的 NLR、PLR、SIII、SIRI、AISI 和 SIMI 平均值明显高于第 1 组（NLR p = 0.011，SIII p = 0.004，SIRI p = 0.011）：鉴于炎症机制在 SCD 及其相关并发症的发病机制中的关键作用，评估与血细胞相关的炎症标志物可为 SCD 的临床监督和治疗干预提供一种实用且有利的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Graefe’s Archive for Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

5.40

自引率

7.40%

发文量

398

审稿时长

3 months

期刊介绍： Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.